MedTrace Logo

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

NCT03824691 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2021-02-25

No results posted yet for this study

Summary

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial: ARCADIA study

Conditions

  • Bladder Carcinoma

Interventions

DRUG

Cabozantinib

cabozantinib 40 mg orally once daily

DRUG

Durvalumab

1500 mg durvalumab (MEDI4736) IV infusion every 28 days

Sponsors & Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-25
Primary Completion
2023-02-28
Completion
2023-02-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03824691 on ClinicalTrials.gov